BIOLASE, Inc. (BIOL)
- Previous Close
0.1500 - Open
0.1511 - Bid --
- Ask --
- Day's Range
0.1470 - 0.1550 - 52 Week Range
0.1300 - 32.0000 - Volume
758,205 - Avg. Volume
5,734,259 - Market Cap (intraday)
5.025M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-29.4400 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 24, 2005
- 1y Target Est
11.22
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
www.biolase.comRecent News: BIOL
Performance Overview: BIOL
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOL
Valuation Measures
Market Cap
4.99M
Enterprise Value
16.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
0.33
Enterprise Value/EBITDA
-1.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.97%
Return on Assets (ttm)
-28.55%
Return on Equity (ttm)
-602.83%
Revenue (ttm)
49.16M
Net Income Avi to Common (ttm)
-37.62M
Diluted EPS (ttm)
-29.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
6.57M
Total Debt/Equity (mrq)
803.02%
Levered Free Cash Flow (ttm)
-2.27M